ArticleFrontiers in neuroscience2025
An alpha7 nicotinic acetylcholine receptor agonist induces retinal neurogenesis and restores electrophysiological function following blast-induced ocular trauma in adult mice.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Blast-induced ocular trauma is a major cause of vision loss in both civilian and military populations and effective treatments are limited by the adult mammalian retina's inability to regenerate neurons lost to injury or aging. This study evaluated the neurogenic potential of PNU-282987, an alpha7 nicotinic acetylcholine receptor agonist, in an adult mouse model of blast-induced retinal trauma. We tested whether a delayed treatment paradigm, initiated after substantial neuronal loss occurred, could induce neurogenesis and restore retinal function. Methods: Adult mice received a single blast exposure, resulting in a significant reduction in cell counts across all retinal layers and decreased electroretinogram (ERG) amplitudes. One month after injury, when neuronal loss was fully established, daily eye drops of PNU- 282987 were administered for two weeks. Neurogenesis and cellular proliferation were assessed using BrdU incorporation and co-labeling with retinal ganglion cell and photoreceptor markers. Retinal function was evaluated with ERG recordings, and cell counts in treated retinas were compared with untreated blasted eyes and uninjured controls. Results: Delayed PNU-282987 treatment induced robust cellular proliferation and neurogenesis throughout the retina. Treated retinas showed significantly increased retinal ganglion cell and photoreceptor counts compared with untreated blast-injured eyes, reaching levels not significantly different from control retinas. Electrophysiological analysis revealed a significant recovery of ERG amplitudes, returning to baseline levels in most cases. Discussion/Conclusion: These findings demonstrate that PNU-282987-induced neurogenesis is sufficient to restore retinal structure and function even when treatment is initiated one month after blast injury. This work establishes a promising novel therapeutic approach for treating retinal trauma in adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.